Portal Biotechnologies Accelerates Growth with Latest Round Led by NFX, Expanded DARPA Contract, and Broad Adoption Across Top Pharma and Academic Centers
Today, Portal Biotechnologies, Inc. (“Portal”), a cell engineering and drug discovery platform company, announced updates on significant commercial progress and the closing of an oversubscribed $9M financing round led by NFX and participation from existing investors including IA Ventures, Pear VC, Undeterred Ventures, IKJ Capital, and TechU Ventures.
Portal Biotechnologies Announces Over 50 Partnerships and Oversubscribed $7M Seed Round Led by IA Ventures
Today, Portal Biotechnologies, Inc. (“Portal”), a cell engineering platform company, announced an oversubscribed $7M seed round led by IA Ventures with participation from Pear VC, Undeterred Ventures, Page One VC, IKJ Capital and other current investors.
Portal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VC
Today, Portal Biotechnologies, Inc. (“Portal”), a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.
Introducing Portal Biotechnologies
Portal Biotechnologies, Inc., a cell engineering platform company, announced its emergence from stealth today. Established in 2023, Portal is implementing a simplified approach to intracellular delivery, focused on accelerating advances in RNA, gene editing, and AI-driven discovery technologies. The company is committed to ensuring broad accessibility of its platform to enable research and therapeutic applications. Portal was founded by Armon Sharei, PhD., founder and former CEO of SQZ Biotechnologies.
